Windtree Therapeuticsincis A Clinical Stage Biopharmaceutical Company Dedicated To Developing Innovative Therapies For Severe Acute Conditionsparticularly In Cardiovascular And Pulmonary Diseasesthe Company Focuses On Addressing Significant Unmet Medical Needs By Advancing Both Early And Late Stage Interventions For Critical Health Issues The Company S Product Portfolio Includes Istaroximea Phase Ii Candidate Aimed At Improving Cardiac Function In Acute Decompensated Heart Failure And Cardiogenic Shockwindtree Also Develops Serca2A Activators For Chronic Heart Failureaerosurf And Kl4 Surfactant For Treating Respiratory Distress Syndrome In Premature Infantsand Rostafuroxin For Genetically Associated Hypertensiontheir Proprietary Aerosol Delivery System Technology Enhances The Treatment Of Respiratory Disorders Windtree Therapeutics Operates On A Licensing Business Modelpartnering With Other Organizations To Advance Its Product Development And Commercialization Effortswith A Small Team Of Around 20 Employeesthe Company Is Committed To Providing Healthcare Providers With Therapies That Improve Current Standards Of Care
No conferences found for this company.
| Company Name | Windtree Therapeutics Inc |
| Country |
United States
|
| Address | N/A |
| Telephone | N/A |
| N/A |
